REDMOND, Washington, October 8 /PRNewswire/ --

Archus Orthopedics, Inc. today announced the first human use of its facet replacement technology to complement an artificial disc. The landmark case was performed by Dr. Karin Buttner-Janz, Dr. Hansen Yuan and Dr. Friedrich Kleinod at the Vivantes Clinic in Berlin, Germany, and involved a patient who previously underwent disc replacement surgery and later developed symptomatic facet joint degeneration. "Generally in this situation the patient is converted to spine fusion," said Dr. Karin Buttner-Janz. "With the Archus facet replacement system, we are now able to allow these patients to keep their artificial disc, retain motion, and avoid fusion," she added.

SAN JOSE, California, October 8 /PRNewswire/ --

- Improved accuracy increases energy availability up to 15% and additional monitoring functions ensure higher safety

Atmel(R) Corporation (Nasdaq: ATML) announced today a family of single-chip Li-ion battery management devices. Combining Atmel's patented high voltage manufacturing process and AVR(R) microcontrollers' technology, the new family gives an extremely high analog accuracy at very low power consumption, while ensuring that portable handheld applications have all the necessary safety functions.

READING, England, October 8 /PRNewswire/ -- Ricardo Eletro, a Brazilian consumer electronics retailer, has selected Wipro Retail, a leading international IT and business services company, to help the business improve its IT systems to compete in one of the world's largest retail markets.

The retailer, which has over 240 stores across Brazil, wants to improve its IT systems with Wipro Retail, so it can support the company's expansion plans, while improving customer service levels and increasing profitability. Solutions will be built using Oracle's Retail Business Suite.

SAN DIEGO, October 8 /PRNewswire/ --

- Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant

Nventa Biopharmaceuticals Corporation (TSX: NVN) today presented positive data from preclinical studies using its proprietary Toll-like Receptor 3 agonist, Poly IC-Poly Arginine (Poly-ICR), at the World Vaccine Congress 2008 in Lyon, France. Study results demonstrated Poly-ICR to be a potent vaccine adjuvant targeting the Toll-like Receptor 3 (TLR3) pathway. Data showed that Poly-ICR, in combination with model antigens, elicits strong anti-target antibody and CD8 T-cell immune responses. These findings demonstrate the versatility of Poly-ICR, suggesting that the compound may possess broad potential for use in both therapeutic and prophylactic vaccines.

LONDON, October 8 /PRNewswire/ --

- Video Sharing Rises as Internet Makes Celeb Status More Achievable

Arguments over the remote control may be a thing of the past as more than half of Britons now use social media to share their lives online more than they watch television, according to new research from Flip Video.

More than half (58%) of 18 to 24 year olds visit a social networking site every day with 42% of 25 to 34 year olds admitting the same frequency. TV is now really taking a back seat for this audience, with 61% of 18 to 24 year olds and over half of 25 to 34 year olds spending more time online than watching TV.

NEW YORK, October 8 /PRNewswire/ --

- Agreement Follows Recent Grant by Intellect of License to Wyeth (NYSE: WYE) and Elan Pharma International Ltd.

Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has entered into an Option Agreement with a top-tier global pharmaceutical company regarding the right to purchase a license to certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease.